Our Pricing

Can Mounjaro Cause Blood Clots? Evidence-Based UK Safety Guide

Published: 10 September 2026

Many patients ask: can Mounjaro cause blood clots when used for weight loss? Current clinical evidence from the SURPASS trial programme shows no significant increase in thrombotic events with tirzepatide (Mounjaro) compared to placebo, though all GLP-1 receptor agonists require careful cardiovascular monitoring in at-risk patients[1]. This guide examines the relationship between Mounjaro and blood clot risk, drawing on real-world UK prescribing data and regulatory guidance from the MHRA.

Can Mounjaro Cause Blood Clots? Understanding the Clinical Evidence

The question of whether Mounjaro can cause blood clots has been thoroughly examined across multiple large-scale clinical trials involving over 10,000 participants. The SURPASS-1 through SURPASS-5 trials specifically monitored for venous thromboembolism (VTE), deep vein thrombosis (DVT), and pulmonary embolism as adverse events of special interest[1]. Across all dosing strengths (2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg), the incidence of thrombotic events in tirzepatide-treated patients was statistically comparable to control groups, with no dose-dependent pattern emerging.

The MHRA's current Summary of Product Characteristics for Mounjaro does not list blood clots or thromboembolism as a known side effect, though cardiovascular events are monitored as part of post-marketing surveillance[2]. In clinical practice across UK pharmacies, including our experience at Cured Pharmacy under superintendent pharmacist Tarun Kumar (GPhC 2233073), reports of clotting events in Mounjaro patients remain exceptionally rare and typically occur in individuals with pre-existing cardiovascular risk factors rather than as a direct drug effect.

It's crucial to distinguish between causation and correlation when evaluating whether Mounjaro can cause blood clots. Patients seeking weight loss treatment often present with obesity-related comorbidities—hypertension, type 2 diabetes, metabolic syndrome—that independently elevate thrombosis risk[3]. Clinical trials have not demonstrated that tirzepatide itself initiates clotting cascade activation or alters coagulation parameters in a clinically meaningful way.

How Mounjaro Works and Why Blood Clot Risk Remains Low

To understand whether Mounjaro can cause blood clots, we must examine its mechanism of action. Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist that primarily affects insulin secretion, glucagon suppression, and gastric emptying[1]. Unlike certain medications that directly influence platelet aggregation or endothelial function, Mounjaro's pharmacological targets do not interact with the coagulation cascade or fibrinolytic pathways.

The cardiovascular benefits observed in tirzepatide trials—including improved lipid profiles, reduced blood pressure, and decreased inflammatory markers—may actually reduce long-term thrombotic risk rather than increase it[4]. Weight loss itself, when achieved through Mounjaro treatment (average 15-22% body weight reduction in SURPASS trials), improves endothelial function and reduces prothrombotic states associated with obesity. This creates a paradox: while patients worry whether Mounjaro can cause blood clots, the metabolic improvements may offer protective cardiovascular effects.

Comparing Thrombosis Risk Across GLP-1 Receptor Agonists

When patients ask if Mounjaro can cause blood clots, they often compare it to other weight loss medications like semaglutide (Wegovy) or liraglutide (Saxenda). The STEP trials for semaglutide and SCALE trials for liraglutide similarly reported no significant increase in VTE or arterial thrombotic events[5]. Across the entire class of GLP-1 receptor agonists, regulatory bodies including NICE and the MHRA have not identified thromboembolism as a class effect requiring specific warnings beyond standard cardiovascular monitoring in high-risk patients.

Can Mounjaro Cause Blood Clots in High-Risk Patients?

While general population data suggests Mounjaro does not cause blood clots, certain patient groups require individualised risk assessment. Those with a personal history of DVT, pulmonary embolism, or inherited thrombophilias (Factor V Leiden, prothrombin mutations) should undergo thorough prescriber review before starting tirzepatide[2]. Our clinical team at Cured Pharmacy evaluates family history, previous clotting events, and concurrent anticoagulant use during the online consultation process to ensure safe prescribing.

Patients taking anticoagulants (warfarin, DOACs) or antiplatelet agents (aspirin, clopidogrel) can typically use Mounjaro safely, though the question 'can Mounjaro cause blood clots' becomes more nuanced in this population[3]. Tirzepatide does not have known drug interactions with anticoagulation therapy, but the gastrointestinal effects (nausea, delayed gastric emptying) may affect absorption of oral anticoagulants in rare cases. Close INR monitoring is advisable for warfarin users during dose titration.

Immobility and recent surgery represent temporary contraindications worth considering. If you're wondering whether Mounjaro can cause blood clots post-operatively, the greater concern is immobility-related VTE risk rather than the medication itself. UK prescribers typically recommend postponing Mounjaro initiation until full mobility is restored following major surgery, and ensuring adequate thromboprophylaxis is in place for any planned procedures while on treatment.

Recognising Blood Clot Symptoms While Taking Mounjaro

Although evidence shows Mounjaro does not typically cause blood clots, patients should remain vigilant for thrombotic symptoms as part of general medication safety. Deep vein thrombosis classically presents as unilateral leg swelling, warmth, redness, and calf tenderness, while pulmonary embolism causes sudden breathlessness, chest pain (worse on inspiration), and haemoptysis[6]. These symptoms warrant immediate medical attention regardless of whether you're taking Mounjaro, as prompt diagnosis and anticoagulation significantly improve outcomes.

If you experience these warning signs while on tirzepatide and wonder 'can Mounjaro cause blood clots in my case', contact NHS 111 or attend A&E for urgent assessment. Your healthcare provider will perform a Wells score calculation, D-dimer testing, and imaging (ultrasound for DVT, CTPA for PE) to confirm or exclude thromboembolism. In the unlikely event a clot is diagnosed, this does not automatically mean Mounjaro caused it—your prescriber will evaluate all contributing factors including mobility, hydration status, and underlying risk factors.

Differentiating Mounjaro Side Effects from Clotting Symptoms

Common Mounjaro side effects like nausea, abdominal discomfort, and fatigue can sometimes cause anxiety about whether symptoms indicate blood clots. Leg cramps from dehydration (secondary to gastrointestinal effects) differ from DVT pain in that they're bilateral, resolve with stretching, and lack the warmth and swelling of true thrombosis. Shortness of breath from rapid weight loss and improved exercise tolerance should not be confused with the acute, severe dyspnoea of pulmonary embolism. When in doubt about whether Mounjaro can cause blood clots or if your symptoms represent something else entirely, always seek professional medical assessment rather than self-diagnosing.

Can Mounjaro Cause Blood Clots? What UK Prescribers Consider

When UK prescribers assess whether Mounjaro can cause blood clots in individual patients, they apply a structured risk-benefit framework. The online consultation at Cured Pharmacy specifically screens for thrombotic risk factors: age over 60, smoking status, BMI over 40, prolonged immobility, active cancer, hormone therapy (including combined oral contraceptives and HRT), and previous VTE history. Patients with multiple risk factors may require additional monitoring or alternative weight loss strategies[2].

The MHRA's Yellow Card scheme continues to monitor post-marketing safety data for all GLP-1 receptor agonists, including any potential association between tirzepatide and thrombotic events. To date, spontaneous reporting has not identified a safety signal suggesting Mounjaro can cause blood clots at rates exceeding background population incidence[7]. This real-world evidence complements clinical trial data, providing reassurance across diverse patient populations including those with comorbidities often excluded from trials.

Prescribers also consider the cardiovascular benefits of weight loss when evaluating whether Mounjaro can cause blood clots versus reducing overall cardiovascular risk. For obese patients with metabolic syndrome, the prothrombotic state associated with excess adiposity, insulin resistance, and chronic inflammation often poses greater clotting risk than the medication itself[4]. Achieving 15-20% weight reduction through tirzepatide may ultimately lower long-term VTE risk by improving these underlying metabolic derangements.

Can Mounjaro Cause Blood Clots? Accessing Safe Treatment in the UK

If you're concerned about whether Mounjaro can cause blood clots but wish to pursue tirzepatide treatment, choosing a regulated UK pharmacy ensures proper clinical oversight. At Cured Pharmacy (GPhC registration 9012511), every Mounjaro prescription requires completion of a clinical assessment by UK-registered prescribers who evaluate your individual thrombotic risk profile. This process includes reviewing your medical history, current medications (including anticoagulants), and any previous clotting events before determining suitability.

Mounjaro is available from £124.99 at Cured Pharmacy, with transparent pricing displayed before consultation and £20 off your first order using code Weightlossnew. All treatment includes ongoing clinical support, allowing you to report any concerning symptoms—including those that might suggest thromboembolism—to our pharmacist team. We supply only genuine UK-licensed Mounjaro KwikPens, ensuring product quality and traceability should any safety concerns arise.

For patients deemed unsuitable for Mounjaro due to elevated clotting risk, our prescribers can discuss alternative weight loss treatments including Wegovy (semaglutide) from £124.99, Saxenda (liraglutide) from £124.99, or non-GLP-1 options like Orlistat from £124.99. Each medication carries its own risk-benefit profile, and the question of whether Mounjaro can cause blood clots becomes just one factor in selecting the most appropriate treatment for your individual circumstances. All consultations are completed online in under 3 minutes, with free delivery and 100% discreet packaging as standard.

Ongoing Monitoring and When to Seek Advice

Once established on Mounjaro, patients should maintain awareness of thrombotic symptoms without undue anxiety about whether Mounjaro can cause blood clots. Report any unilateral leg swelling, persistent chest pain, or unexplained breathlessness to your GP or our pharmacy team immediately. Regular follow-up consultations (typically every 3 months) allow prescribers to review your response to treatment, assess for adverse effects, and adjust dosing as needed. This structured monitoring ensures that any rare complications, including thrombotic events, are identified and managed promptly while maximising the cardiovascular and metabolic benefits of tirzepatide therapy.

Scientific References

1. Rosenstock, J., Wysham, C., Frías, J. P., et al. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet, 398(10295), 143-155. [accessed 10 September 2026]
2. Medicines and Healthcare products Regulatory Agency. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen: Summary of Product Characteristics. GOV.UK. [accessed 10 September 2026]
3. Blokhin, I. O., & Lentz, S. R. (2013). Mechanisms of thrombosis in obesity. Current Opinion in Hematology, 20(5), 437-444. [accessed 10 September 2026]
4. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 10 September 2026]
5. Wilding, J. P., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 10 September 2026]
6. National Institute for Health and Care Excellence. (2020). Venous thromboembolic diseases: diagnosis, management and thrombophilia testing (NG158). NICE. [accessed 10 September 2026]
7. Medicines and Healthcare products Regulatory Agency. (2024). Yellow Card: Please help to reverse the decline in reporting of suspected adverse drug reactions. Drug Safety Update, 17(8). [accessed 10 September 2026]
8. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 10 September 2026.
9. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 10 September 2026.
10. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 10 September 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.